Compare FSBW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBW | TSHA |
|---|---|---|
| Founded | 1936 | 2019 |
| Country | United States | United States |
| Employees | 537 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.6M | 1.7B |
| IPO Year | 2011 | 2020 |
| Metric | FSBW | TSHA |
|---|---|---|
| Price | $44.15 | $5.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $46.00 | $11.63 |
| AVG Volume (30 Days) | 17.2K | ★ 2.0M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 2.07 | N/A |
| Revenue | $4,612,000.00 | ★ $9,773,000.00 |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $10.47 | $1,152.42 |
| P/E Ratio | $21.42 | ★ N/A |
| Revenue Growth | ★ 44.80 | 17.28 |
| 52 Week Low | $36.85 | $2.72 |
| 52 Week High | $45.85 | $7.30 |
| Indicator | FSBW | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 33.36 |
| Support Level | $41.09 | $4.37 |
| Resistance Level | $44.89 | $5.07 |
| Average True Range (ATR) | 0.73 | 0.25 |
| MACD | 0.14 | -0.04 |
| Stochastic Oscillator | 67.77 | 10.85 |
FS Bancorp Inc is the holding company of First Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.